CAGRI-SEMA 10MG: CAGRILINTIDE 5MG + SEMAGLUTIDE 5MG

Description

Legal Disclaimer
This information has not been reviewed or endorsed by the US FDA. It is provided solely for educational and research purposes. Cagri-Sema (Cagrilintide + Semaglutide) is not approved for medical use, human consumption, or as a therapeutic treatment in this context.

Product Details

• Total Quantity: 10mg per vial

  • Cagrilintide: 5mg

  • Semaglutide: 5mg

• Form: Lyophilized dual-peptide powder

• Packaging: Secure, sealed, and tamper-proof sterile vial

• Source: High-quality lab-grade peptides, independently third-party tested

• Purity: ≥98% (HPLC and mass spectrometry verified)

• Note: This product is sold in powder form and must be reconstituted prior to laboratory use

Overview of Cagri-Sema’s Research Profile

Cagri-Sema is a dual-pathway metabolic research formulation combining Cagrilintide, a long-acting amylin receptor agonist, with Semaglutide, a GLP-1 receptor agonist peptide. This combination is designed for advanced research into energy regulation, neuroendocrine signaling, and integrated metabolic feedback mechanisms.

In controlled laboratory environments, Cagri-Sema is used to explore how amylin and GLP-1 signaling pathways interact at both peripheral and central regulatory levels. The formulation allows researchers to evaluate prolonged peptide-receptor engagement, signal amplification, and coordinated feedback across multiple metabolic control systems.

Research Specifics

Cagri-Sema has been investigated in non-clinical research for its involvement in:

• Amylin Receptor Signaling Studies
  Examining long-acting receptor activation, signal persistence, and pathway desensitization via Cagrilintide.

• GLP-1 Receptor Pathway Analysis
  Modeling incretin-related signaling, receptor binding dynamics, and downstream intracellular cascades.

• Dual-Pathway Interaction Research
  Investigating synergistic effects between amylin and GLP-1 receptor systems within metabolic regulation frameworks.

• Neuroendocrine Communication Models
  Exploring peptide-mediated signaling between peripheral metabolic cues and central regulatory pathways.

• Peptide Stability & Duration Studies
  Assessing long-acting peptide modifications, degradation resistance, and extended signaling kinetics.

Key Features

• Peptide Composition: Dual-agonist metabolic research blend

• Total Content: 10mg per vial (5mg Cagrilintide + 5mg Semaglutide)

• Form: Lyophilized powder for reconstitution

• Purity: ≥98% research-grade

• Laboratory Stability: Optimized for extended experimental protocols when stored appropriately

Potential Applications

Researchers may explore Cagri-Sema in studies involving:

• Integrated metabolic signaling pathways

• Amylin and GLP-1 receptor interaction analysis

• Energy balance and nutrient-response modeling

• Neuroendocrine feedback loop investigations

• Long-acting peptide synergy and optimization research

Specifications

This product is supplied in a sterile, tamper-evident vial to preserve molecular integrity and purity. Reconstitution should be performed using appropriate laboratory-grade diluents and standard peptide-handling protocols. Proper cold storage is recommended to maintain stability.